title: References - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 411/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  References
  |
  NICE Guideline 2015. Gastro-oesophageal reflux disease in children and young people: diagnosis and management. Published: 14 January 2015. nice.org.uk/guidance/ng1.
  Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E,Liptak G, Mazur L, Sondheimer J, Staiano,A, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. JPGN 2009;49:498–547.
  Shawyer AC, D'Souza J, Pemberton J, Flageole H. The management of postoperative reflux in congenital esophageal atresia-tracheoesophageal fistula: a systematic review. Pediatr Surg Int [Internet]. 2014 [cited 2014 Oct];30(10):987-96. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25011995.
  TigheM, AfzalNA, BevanA,HayenA,MunroA, Beattie RM. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD008550. DOI: 10.1002/14651858.CD008550.pub2.
  Freedberg DE, Lamouse-Smith ES, Lightdale JR, Jin Z, Yang YX, Abrams JA. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis [Internet]. 2015 [cited 2015 Sep 15];61(6):912-7. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=26060292
  Jimenez J, Drees M, Loveridge-Lenza B, Eppes S, delRosario F. Exposure to Gastric Acid-Suppression Therapy Is Associated With Health Care- and Community-Associated Clostridium difficile Infection in Children. J Pediatr Gastroenterol Nutr [Internet]. 2015 [cited 2015 Aug];61(2):208-11. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25806678
  Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol [Internet]. 2015 [cited 2015 Aug];80(2):200-8. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25752807
  Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr [Internet]. 2009 [cited 2009 Oct];155(4):516-21. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=19540518.
  Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A, Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics [Internet]. 2006 [cited 2006 May];117(5):e817-20. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=16651285.
  Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001;20:1119–24.
  More K, Athalye-Jape G, Rao S, Patole S.Association of inhibitors of gastric acid secretion and higher incidence of necrotizing enterocolitis in preterm very low-birth-weight infants. Am J Perinatol. 2013 Nov;30(10):849-56
  Kearns GL; Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatric Gastroenterology & Nutrition 2003; 37 Suppl 1:S52-9.
  Omari TI; Haslam RR; Lundborg P; Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatric Gastroenterology & Nutrition 2007; 44(1):41-4.
  Hoyo-Vadillo C; Venturelli CR; Gonzalez H; Romero E; Cervantes R; Mata N; Ortiz AC; Rincon V; Zarate F; Sosa C; Ramirez-Mayans J. Metabolism of omeprazole after two oral doses in children 1 to 9 months old. Proceedings of the Western Pharmacology Society2005; 48:108-9.
  Faure C; Michaud L; Shaghaghi EK; Popon M; Turck D; Navarro J; Jacqz-Aigrain E. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. Journal of Pediatric Gastroenterology & Nutrition 2001; 33(2):144-8.
  Kaufman SS; Lyden ER; Brown CR; Davis CK; Andersen DA; Olsen KM; Bergman KL; Horslen SP; Sudan DL; Fox IJ; Shaw Jr BW; Langnas AN. Omeprozole therapy in pediatric patients after liver and intestinal transplantation. J Pediatric Gastroenterology & Nutrition 2002;34(2):194-8.
  Chen LL, Gao WY, Johnson AP, Niak A, Troiani J, Korvick J, Snow N, Estes K, Taylor A, Griebel D. Proton Pump Inhibitor Use in Infants: FDA Reviewer Experience. JPGN 2012;54(1):8–14.doi: 10.1097/MPG.0b013e31823890b4.
  Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci. 2008;53(2):385–93.
  http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022056s000medr.pdf. Accessed on July 22 2016.
  Micromedex 2.0
  Product Information: PRILOSEC oral delayed-release capsules, omeprazole oral delayed-release capsules. AstraZeneca LP (per FDA), Wilmington, DE, 2014.
  The Australian Journal of Hospital Pharmacy 1998:28:174-6.
  |
  |
  | |